Approximately 15%–20% of all cases are considered triple-negative breast cancer (TNBC) because of undetectable levels of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) protein at the time of diagnosis. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.